Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$43.26 USD

43.26
970,941

+0.62 (1.45%)

Updated May 31, 2024 04:00 PM ET

After-Market: $43.27 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test

by Zacks Equity Research

QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.

QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.

QGEN vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

QGEN vs. TECH: Which Stock Is the Better Value Option?

Company News for Apr 8, 2021

by Zacks Equity Research

Companies In The News Are: QGEN, MSM, LI, GEO.

Trina Mukherjee headshot

3 GARP MedTech Stocks to Snap Up Despite Pandemic Woes

by Trina Mukherjee

Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.

QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio

by Zacks Equity Research

QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.

QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA

by Zacks Equity Research

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement

by Zacks Equity Research

Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes

by Zacks Equity Research

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing

by Zacks Equity Research

QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.

QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

by Zacks Equity Research

QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater

by Zacks Equity Research

Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Qiagen (QGEN) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise

by Zacks Equity Research

QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.

The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics

Urmimala Biswas headshot

Testing Space in Focus Again Thanks to New Wave of Coronavirus

by Urmimala Biswas

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Trina Mukherjee headshot

3 Soaring MedTech Stocks That Might Lose Ground in 2021

by Trina Mukherjee

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio

by Zacks Equity Research

Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.